In vivo evidence supports the effectiveness of the longevity-associated protein LAV-BPIFB4 in reducing adipose tissue-derived mediators of systemic inflammation to prevent vascular insult and atheromatous change

体内实验证据支持长寿相关蛋白LAV-BPIFB4能够有效减少脂肪组织来源的全身炎症介质，从而预防血管损伤和动脉粥样硬化。